Dipyridamole: A Drug with Unrecognized Antioxidant Activity

Author(s): Marco Ciacciarelli, Chiara Zerbinati, Francesco Violi, Luigi Iuliano

Journal Name: Current Topics in Medicinal Chemistry

Volume 15 , Issue 9 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator. Among cellular targets, it inhibits phosphodiesterases and raises extracellular levels of adenosine through inhibition of adenosine reuptake by red blood cells. As a consequence, endocellular levels of cyclic nucleotides are upregulated. The rise of cGMP in vascular smooth mu scle cells and of cAMP in platelets provide the mechanism of vasodilation and antithrombosis, which are further potentiated by the release of PGI2 consequent on the increase in endothelial cell cAMP. These effects support the use of dipyridamole in cardiovascular diseases in which the drug is approved for the secondary prevention of cerebrovascular events. On the other hand, dipyridamole has been shown to possess a potent, little perceived, antioxidant activity of potential use in the several fields where pathophysiological pathways are dependent on oxidative stress, including those occurring in atherosclerosis, thrombosis, CNS-related diseases, and cancer.

Keywords: Antioxidant, Atherosclerosis, Cancer, Coronary artery disease, Dipyridamole, Ischemia-reperfusion injury, Neurodegeneration, Neuroprotection.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [822 - 829]
Pages: 8
DOI: 10.2174/1568026615666150220111942
Price: $65

Article Metrics

PDF: 46
PRC: 1